Abstract
Malemud CJ. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 2018; 10 (5–6): 117–127. DOI: 10.1177/1759720X18776224
This article has the following corrections:
The first sentence on page 120 (first column, third line) should read “Tofacitinib was reported to selectively inhibit JAK1 and JAK3 over JAK2, exhibiting ~4-fold selectivity for JAK1 (IC50=15.1) versus JAK3 (IC50=55.0 nM) and ~5-fold selectivity for JAK1 versus JAK2 (IC50=77.4 nM)55.
Reference 55, on page 125, should read “Clark JD, Flanagan ME and Telliez JB. Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases. J Med Chem. 2014; 57 [12]:5023–5038.”
The online version of the article has been corrected.